Levin Capital Strategies L.P. bought a new position in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 8,377 shares of the exchange traded fund’s stock, valued at approximately $748,000.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in XBI. EPG Wealth Management LLC grew its position in SPDR S&P Biotech ETF by 152.7% during the 3rd quarter. EPG Wealth Management LLC now owns 460 shares of the exchange traded fund’s stock worth $34,000 after purchasing an additional 278 shares during the period. Tennessee Valley Asset Management Partners acquired a new stake in shares of SPDR S&P Biotech ETF during the 4th quarter valued at about $44,000. Wetzel Investment Advisors Inc. acquired a new stake in shares of SPDR S&P Biotech ETF during the 4th quarter valued at about $45,000. Life Planning Partners Inc acquired a new stake in shares of SPDR S&P Biotech ETF during the 4th quarter valued at about $64,000. Finally, Albion Financial Group UT acquired a new stake in shares of SPDR S&P Biotech ETF during the 4th quarter valued at about $69,000.
SPDR S&P Biotech ETF Stock Up 1.4 %
Shares of NYSEARCA:XBI traded up $1.24 during trading on Thursday, reaching $88.57. 7,996,242 shares of the company’s stock traded hands, compared to its average volume of 11,675,642. SPDR S&P Biotech ETF has a fifty-two week low of $63.80 and a fifty-two week high of $103.52. The firm has a market cap of $6.75 billion, a PE ratio of 11.47 and a beta of 1.11. The company has a 50-day simple moving average of $92.28 and a 200-day simple moving average of $85.06.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Further Reading
- Five stocks we like better than SPDR S&P Biotech ETF
- What is Put Option Volume?
- Meta Stock: 3 Reasons This Stumble Is a Golden Buying Opportunity
- How to Find Undervalued Stocks
- 3 Staples Stocks to Cushion Lower Consumer Sentiment
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Zillow’s Earnings Dip: An Opportunity for Visionaries
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.